Subscribe To Our Free Newsletter |
Dishman Pharma gains 2%; clarifies on Clovis issue
The company said it has not received any letter of warning from the USFDA.
Subscribe To Our Free Newsletter |
EvoLve theme by Theme4Press • Powered by WordPress & Rakesh Jhunjhunwala Latest Stock Market News
The Most Valuable Commodity Is Information!